The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Attention Score in Context
| Title |
Tamsulosin vs. Tadalafil as medical expulsive therapy for distal ureteral stones: a systematic review and meta-analysis
|
|---|---|
| Published in |
International Brazilian Journal of Urology, December 2023
|
| DOI | 10.1590/s1677-5538.ibju.2023.0345 |
| Pubmed ID | |
| Authors |
Mikhael Belkovsky, Giulia Veneziani Zogaib, Carlo Camargo Passerotti, Everson Luiz de Almeida Artifon, José Pinhata Otoch, José Arnaldo Shiomi da Cruz |
| Abstract |
Medical expulsive therapy (MET) is recommended for distal ureteral stones from 5 to 10 mm. The best drug for MET is still uncertain. In this review, we aim to compare the effectiveness of tadalafil and tamsulosin for distal ureteral stones from 5 to 10 mm in terms of stone expulsion rate (SER), stone expulsion time (SET) and the side effect profile. A comprehensive literature search was conducted on MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Scopus and Web of Science, from inception until April 2023. Only randomized controlled trials were included in the analysis. Eleven publications with 1,330 patients were included. We observed that tadalafil has a higher SER (OR 0.55, CI 95% 0.38;0.80, p=0.02, I2=52%) and the same efficacy in SET (MD 1.07, CI 95% -0.25; 2.39, p=0.11, I2=84%). No differences were found when comparing side effects as headache, backache, dizziness, and orthostatic hypotension. Tadalafil has a higher stone expulsion rate than tamsulosin as a medical expulsive therapy for patients with distal stones from 5 to 10 mm without differences in side effects. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Argentina | 3 | 27% |
| Peru | 1 | 9% |
| Unknown | 7 | 64% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 64% |
| Practitioners (doctors, other healthcare professionals) | 3 | 27% |
| Scientists | 1 | 9% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2023.
All research outputs
#4,710,230
of 26,180,352 outputs
Outputs from International Brazilian Journal of Urology
#66
of 736 outputs
Outputs of similar age
#74,341
of 381,875 outputs
Outputs of similar age from International Brazilian Journal of Urology
#2
of 10 outputs
Altmetric has tracked 26,180,352 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 736 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 381,875 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 8 of them.